“When stocks are attractive, you buy them. Sure, they can go lower. I've bought stocks at $12 that went to $2, but then they later went to $30. You just don't know when you can find the bottom.” -Peter Lynch

Fun fact for Peter Lynch, he coined the term "10 bagger".

Some people on this board seem to lack patience, a necessary quality for any investor imo.

Please stay on topic.

Ahh international diversification, I like it. Q-10 also looked okay with the resolution of $200,000 in debt and the fact that it did not grow! With the vote in November, more possible dispensary acquisitions, the E-joints, and eventually a FDA submission, things are starting to revvvv up. Chart is also setting up...

I also imagine CBIS' Ejoint will be better than Vapor Rush. They seem to use THC as their primary ingredient whereas Cannabis Science will be trying to use whole plant extracts that are better for the user medicinally.

Monday may hold the answer to your question. It looks like it is...

Definitely.

I think so too.

Ah thank you for the information. Although we may have lost some of the revenues anticipated for the quarterly, I think resolving some of the debt will be huge. "Mr. Cowan added, "I am also very pleased to report that we are currently converting most of the company's debt into common equity. Adding revenues, eliminating debt, and clarifying the company's financial structure should help provide a higher per share price and valuation for the company. As a result of the debt conversions, the acquisition, and corporate expansions there are currently 65,570,574 shares outstanding and management expects to retire most of its debt by the end of June thereby eliminating a major source of risk. These developments should allow some of the larger funds and fund managers to invest substantially more in the company because of the reflection of our greater financial strength." May 24, 2010.

I also wonder what will be done with the millions of shares that were to be used for MPM and Rockbrook inc. More acquisitions incoming? I do like how the O/S has not changed since this PR as well.

Rereading the NT 10-Q, I just noticed it read 5 calendar days. I'm thinking quarterly this weekend then, any thoughts?

http://www.rollingstone.com/politics/news/17390/192121

In regards to Prop 215 it has been expanded to, "SB 420 (Health & Safety Code 11362.7-8), which (1) authorizes caregivers who provide marijuana to patients to be compensated for the costs of their services, though not on a for-profit basis; and (2) allows patients to form cultivation "collectives" or "cooperatives." On careful examination, however, neither of these provisions provides a green light for sales of cannabis. Those dispensaries that are selling marijuana over the counter accordingly do so at the tolerance of local authorities.". Still looks pretty non-profit at the moment. As you are saying Prop 19 passing will make this look really good.

Ya. The main thing I will be looking at is to see how much debt was resolved.

Me too. A good day today would set up next week beautifully as well.

Not a bad start today.

CBIS looking for a bounce. Growth Q2 expected soon as well.

Scam or not a scam that is the question

It looks I will be jumping aboard soon. Will be eying this manana. I can't believe MFLI has gotten so cheap.

Next year 11/11/11 11:11 AM should be cool imo.

Actually we are forming a bottom that we haven't for the longest time. Do you read charts? Also if the quarterly shows that a large portion of debt has been resolved, expect an upward move. The quarterly is expected tomorrow or Monday if you didn't know

Hey Clay, could you do an annotated chart for CBIS? Looks like it might bounce imo. Also had three PR's yesterday, two of which were licensing agreements.

The truth.

"COLORADO SPRINGS, Colo., Jun 15, 2010 (GlobeNewswire via COMTEX) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products announces Federal Court order for CBIS shares owned by Cannex Therapeutics controlled by Steve Kubby to be cancelled and re-issued to K&D. Both K&D and Cannabis Science denounce the "slanderous, malicious attacks" on the Company by its fired CEO Steve Kubby. Both parties are assessing additional legal action against Steve Kubby for his continued attacks against Cannabis Science, its shareholders, and the company's current management team as a safeguard to defend shareholder interest.

Cannabis Science and its former management group are working together to address Steve Kubby's false statements regarding the company, its transactions, its shareholders, and its current and future financial status. Currently, Cannabis Science lawyers are looking into possible legal action against Steve Kubby and those websites and blogs that knowingly enable his libelous statements and fraudulent behavior. Steve Kubby's attempts to discredit Cannabis Science, urging CBIS shareholders to sell their shares so that they can invest in his private company may raise some serious legal issues.

Yesterday, K&D President Charlie Stidham spoke to Cannabis Science management and stated, "I spoke to Steve Kubby and told him to never use my name without my consent and stop all the slanderous, malicious attacks against Cannabis Science and its team."

Stidham further stated, "I will exercise my legal options to cause these malicious, calculated attacks on the Company and myself to cease. Steve Kubby assured me he would not continue with the attacks against the Company."

Mr. Stidham also emphasized, "I'm very pleased with Dr. Robert Melamede and Richard Cowan being the control shareholders in Cannabis Science and the job they have done progressing the Company since Steve Kubby. Our group understands the real potential with Dr. Bob and Richard in control of Cannabis Science and we are very pleased to help them out anyway we can. These gentlemen are clearly the leaders in the industry, and they have been very clear with the path they are heading down. To see them build the company this quickly having so many opportunities by far overshadows over any single lozenge, which now is obviously just a minimal part of the Cannabis Science big picture."

Dr. Robert Melamede, Cannabis Science Inc. President and CEO, states, "Up until now, we have chosen to ignore Steve Kubby's attacks. We were giving him time to regain balance after having to remove him from his duties as President and CEO. However, his repeated attacks in an effort intended to destroy our credibility, at any cost, with his unethical statements and news releases have now raised questions from our investors, and have apparently affected our share price. Rather than answering individual inquiries we chose to clarify the situation with this press release."

Richard Cowan, Cannabis Science CFO, added, "It is important to reiterate that Cannabis Science is a fully reporting audited company, complying in every way with SEC regulations. Further, Cannabis Science fired Steve Kubby because of his questionable financial activities and his apparent inability to understand the basics of corporate governance for a public company. Steve Kubby's continued disregard of basic business practices and ethics underscores the correctness of our earlier decision to terminate him as President and CEO of Cannabis Science."

Cowan noted, "Regarding the recent court settlement order, Steve Kubby has completely misrepresented what has occurred. He claims that a summary judgment for K&D and against him was somehow a victory for him and that Cannabis Science 'no longer exists.' In fact, it had no bearing whatsoever on the legal status of Cannabis Science Inc. and its current management or business plans.

"Earlier, K&D Equity Investments Inc. amicably settled their differences with the current Cannabis Science management team. However, they did not settle with Cannex Therapeutics, Kubby's private company or with Kubby personally. Under the court order, Kubby was forced to give all of his shares in Cannabis Science to K&D and in return he is to be released from further actions against him from K&D on that matter. In order to demonstrate the patent absurdity of the situation, a few of the critical misrepresentations made by Mr. Kubby will be examined."

Cowan further stated, "The notion that Cannabis Science under one of the world's leading experts on cannabinoids would need anything from Steve Kubby is absurd. We are growing very rapidly through strategic acquisitions and partnerships with people who want to work with Dr. Robert Melamede. These developments give us great confidence in the future of Cannabis Science as a major player in the pharmaceutical industry providing alternative medicines in several distribution outlets such as dispensaries, over the counter nutraceutical and FDA approved medicines in several delivery formats such as sprays, creams, extracts, and strips based on whole plant based formulations."

And you must not understand the lozenge in the first place. It was a formulation he had patented, not lozenges in general. You CANNOT PATENT LOZENGES IN GENERAL. TY.

lozenges in general are not patentable but okay.

http://www.c-spanvideo.org/program/295043-1

Well Cannabis(Marijuana) has been shown to be more effective for PTSD and pain management than any other known substance, and that is what Cannabis Science is initially seeking through the FDA. For example, Cannabis has an estimated therapeutic index of 40000 to 1 as compared to aspirin with a therapeutic index of 15. The form I believe is a lozenge but I am not 100% sure about that, as they have not applied to the FDA as of yet, and things can change.

I could rant forever about what I think Cannabis Science could offer to the average dispensary but I think the main things are knowledge and professionalism (quite broad I know). The biggest issues faced by a dispensary are staying compliant with state regulations and growing their medical marijuana with a standardized efficacy. This is a medicine we are dealing with that people are going to be consuming, and I would say a board of doctors, like CBIS has, is essential. Would you rather some random dude grow your medicine for you or doctors with the "know how" and research to be able produce exactly what is best for you. Also, as I stated earlier, staying compliant with state regulations is key. Cannabis Science has a policy advisory board of lawyers for just this purpose. So in summary, I think they can create a better quality of medicine and can also stay ahead of the regulations required to stay open for business.

Also don't forget, the dispensary licensing and their joint venture with Smokefree Innotec are only part of the equation. The BIG thing is getting the funding and patient research in order to get through the FDA. These are just steps to help us get to a billion dollar FDA approved medicine for PTSD and pain management :D

Although I liked the idea of owning MPM, Montana is possibly making some big changes to their dispensary system, and it may be for the best right now that it is canceled. It also sounds to me like Mr. Rosario is going to be liable to pay us damages. Seems pretty clear to me that he broke contractual obligations. It will be very interesting to see this unfold.

I like this set up with Rockbrook Inc. more IMHO.

"Under the terms of the Agreement RockBrook will pay Cannabis Science an initial license fee of USD $25,000, which is payable within the first year of the Agreement. As well, RockBrook will pay Cannabis Science a quarterly royalty payment of 50% of all positive revenues derived from the Cannabis Science Brand of Pharmaceutical Products. If RockBrook enters into any sublicensing agreements, Cannabis Science is entitled to royalty payments of 50% of all positive revenues received by the Licensee for sales of any Cannabis Science Brand of Pharmaceutical Products. Within 2 years of the execution of this Agreement RockBrook will invest a minimum of $250,000 in research and development directly associated with the Cannabis Science Brand of Pharmaceutical Products. RockBrook will also pay to Cannabis Science a yearly renewable license fee, payable annually on the anniversary of the execution of this Agreement, according to the following schedule; First Anniversary payment USD $25,000, Second Anniversary USD $50,000, Third Anniversary USD $75,000, Fourth Anniversary USD $100,000, Fifth and Successive Anniversaries USD $150,000"

I really like this licensing agreement. It also seems to me like this agreement can be made with multiple dispensaries within Colorado...Everyone knows CBIS has the best stuff!

"Management of the Company is currently consulting with legal counsel and intends to proceed with legal action against MPM and its principal shareholder, Mr. Rosio, for breach of the NDA/NCVA that was entered into on June 11, 2010". Sounds to me like we may be making some $$$ and not having to give him any shares for the money. Big legal mistake on Mr. Rosio's part. Tomorrow I will be in communication with a Lawyer that can hopefully fill me in more.

8/18/10 Smokefree Innotec Confirms Joint Venture with Cannabis Science, Examines Potential of Medical Cannabis Market

IRVINE, Calif., Aug 18, 2010 (BUSINESS WIRE) -- Smokefree Innotec, Inc. (Pink Sheets:SFIO) Thomas Schroepfer, CEO, (http://www.sfio.us or http://www.realsmokefree.com) confirmed today the announcement by the Biotech company Cannabis Science (OTCBB:CBIS) regarding entering into a joint venture agreement to develop and market several high-tech smoke-free vaporized medical cannabis pharmaceutical products, as released by CBIS on August 13. He stated, "Pursuant to the joint venture, Smokefree Innotec Inc will supply its high-tech smoke-free vapor technology devices and Cannabis Science will provide all the medical cannabis extract formulations."

George Roth, CFO stated, "Our business of designing, developing, manufacturing and marketing hi-tech, nicotine and non-nicotine cigarette-like delivery devices which are completely smoke and vapor-free and tobacco-free, represents an excellent partnering with Cannabis Science to fill their needs for production and distribution in the fourteen US States that currently approve the medical use of cannabis. This partnering further represents our commitment to continue to expand our network of cutting edge technology partners to create ever expanding product lines, for devices delivering both nicotine and herbal therapeutic extracts, as seen on our web site http://www.sfio.us.";

Mr. Roth added, "It is worth repeating that this partnering with Cannabis Science will put Smokefree Innotec in the forefront of marketing devices delivering medical formulations of pharmacological extracts to dispensaries and healing centers already in existence, in compliance with applicable federal and state regulations. With the anticipated voter approval of Prop 19 in California, we believe the number of dispensaries and related retail establishments for marijuana and marijuana accessories will multiply rapidly.

"From the news reports, a majority of Californians continue to voice their support for Prop. 19, which would eliminate penalties for the private possession and use of marijuana by adults, and allow local governments to regulate retail cannabis production and sales. Further, the results of a series of randomized, placebo-controlled clinical trials assessing the efficacy of inhaled marijuana consistently show that cannabis holds therapeutic value comparable to conventional medications, according to the findings of a 24-page report issued Wednesday to the California state legislature by the California Center for Medicinal Cannabis Research (CMCR)."

(See http://www.cmcr.ucsd.edu/CMCR_REPORT_FEB17.pdf.)

In an earlier release, Dr. Robert Melamede, President and CEO of Cannabis Science Inc., stated, "Many patients smoke medical cannabis because it gives them rapid relief that allows them to monitor their usage. Smokefree Innotec's technology allows the patients even greater convenience and dosage control than smoking, without all of the possible health and social/legal problems associated with smoking. Cannabis Science will provide a variety of standardized medical marijuana formulations to be used with the Smokefree Innotec products, so that patients can self-monitor their dosages. Of course, these products will be of even greater value to patients who do not like to smoke since vaporizing minimizes the irritating and harmful effects caused by direct smoke contacting the lungs."

Mr. Roth added, in San Diego, California alone, a grand jury report "estimated there are at least 5,000 medical marijuana patients in San Diego County, and it's probable there are considerably more. Medical marijuana advocates say there could be 60,000." "There are more marijuana dispensaries in Los Angeles than there are Starbucks," candidate Chris Kelly said in a June 23rd San Diego Tribune article. According to Wikipedia, "Across California there are an estimated 2,100 dispensaries, co-operatives, wellness clinics and taxi delivery services in the sector known as 'cannabusiness.' That is more than all the Starbucks, McDonald's and 7-Eleven outlets in the state put together(17), according to The Sunday Times."

Mr. Schroepfer added, "With our international distribution of Smokefree Innnotec products already well established, the entry into the Medical Cannabis market represents our commitment to significantly expand and distribute new products across North America. Identifying and securing market share of rapidly growing fields such as Medical Cannabis, Military Retail and Government service will continue to be led by the efforts of our partners at Leading Points Corporation. The management of both companies acknowledged their appreciation that they were brought together in this joint venture as another one of the successful business partnerships initiated by Leading Points Corporation (www.leadingpoints.com), whose mission is matching industry leaders in order to capture market share."

About Smokefree Innotec, Inc: www.smokefree-innotec.com

Smokefree Innotec, Inc. is in the business of designing, developing, manufacturing and marketing hi-tech, nicotine and non-nicotine cigarette-like delivery devices which are completely smoke and vapor-free and tobacco-free. Smokefree Innotec's products are designed to protect the non-smoker from second hand smoke and all its effects while providing the smoker a way to enjoy a smoke-free cigarette anywhere, including places where smoking tobacco or similar substances is prohibited. Further, our products will allow the smoker to enjoy smoking either nicotine or flavored non-nicotine cigarettes while not having to worry about the offensive dangers and ill effects of regular cigarette smoking. However Smokefree Innotec products are not intended for any prevention or therapeutic treatment of any disease.

A number of statements referenced in this Press Release are forward-looking statements, which are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995, and within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, and goals, assumption of future events or performance are not statements of historical fact and may be "forward-looking statements." Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this Release may be identified through the use of words such as "expects," "will," "anticipates," "estimates," "believes," or statements indicating certain actions "may," "could," or "might" occur. Such statements reflect the current views of Smokefree Innotec Inc. with respect to future events and are subject to certain assumptions, including those described in this release. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products, services, and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses, and other factors. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. Smokefree Innotec Inc. does not undertake any responsibility to update the "forward-looking" statements contained in this news release. Disclosures made in this Press Release are limited by good business practice and to that permitted to the public by applicable securities regulations, both Federal and State, including rights granted to shareholders under the Nevada Revised Statutes NRS 78.257 regarding limitations of preferential and selective disclosure of confidential Company information.

SOURCE: Smokefree Innotec, Inc.

CONTACT:

Smokefree Innotec, Inc. Kim Carroll, Investor Relations +1-949-813-5729

Copyright Business Wire 2010

-0-

KEYWORD: United States
North America
California
INDUSTRY KEYWORD: Health
Biotechnology
Medical Devices
Pharmaceutical
SUBJECT CODE: Contract/Agreement

8/18/10 Cannabis Science Signs First Licensing Agreement With RockBrook for Manufacturing, Development, and Distribution of the Cannabis Science Brand of Pharmaceutical Products for the State of Colorado as State Legislation Forces Cancellation of RockBrook Acquisition

COLORADO SPRINGS, Colo., Aug 18, 2010 (GlobeNewswire via COMTEX) -- Cannabis Science Inc. (OTCBB:CBIS) a pioneering US biotech company developing pharmaceutical cannabis products, announces that on August 18, 2010, Cannabis Science signed with RockBrook Inc., its first manufacturing and development license for the Cannabis Science Brand of Pharmaceutical Products for the State of Colorado. The licensing agreement grants RockBrook the full latitude and rights to manufacture, develop, produce, distribute, and sell products developed from, or based on Cannabis Science formulations, and delivery systems for the Cannabis Science Brand of Pharmaceutical Products and Cannabis Science Ailment Formulations within the State of Colorado.

Dr. Robert Melamede, Ph. D., Cannabis Science Inc., President & CEO said, "Importantly, unlike big pharma, Cannabis Science will be able to immediately begin using data acquired from RockBrook patients using Cannabis Science Brands to evaluate our medical marijuana prior to FDA clinical trials. We are enthusiastic that our relationship with Mr. Pasquale and RockBrook has been established under a licensing and manufacturing agreement that is compliant with the current Colorado regulatory environment. RockBrook will immediately begin marketing and developing new Cannabis Science Brand of Pharmaceutical Products."

Under the terms of the Agreement RockBrook will pay Cannabis Science an initial license fee of USD $25,000, which is payable within the first year of the Agreement. As well, RockBrook will pay Cannabis Science a quarterly royalty payment of 50% of all positive revenues derived from the Cannabis Science Brand of Pharmaceutical Products. If RockBrook enters into any sublicensing agreements, Cannabis Science is entitled to royalty payments of 50% of all positive revenues received by the Licensee for sales of any Cannabis Science Brand of Pharmaceutical Products. Within 2 years of the execution of this Agreement RockBrook will invest a minimum of $250,000 in research and development directly associated with the Cannabis Science Brand of Pharmaceutical Products. RockBrook will also pay to Cannabis Science a yearly renewable license fee, payable annually on the anniversary of the execution of this Agreement, according to the following schedule; First Anniversary payment USD $25,000, Second Anniversary USD $50,000, Third Anniversary USD $75,000, Fourth Anniversary USD $100,000, Fifth and Successive Anniversaries USD $150,000.

Richard Cowan, Cannabis Science CFO, added, "Due to changes in Colorado Legislation, Cannabis Science was forced to cancel the Share Purchase and Management Consulting Agreements previously signed on May 8, 2010 with RockBrook and its sole shareholder, Mr. Adam Pasquale. On August 1, 2010, the HB 1284 legislation came into effect in the State of Colorado. The new legislation precludes any non-resident from having ownership in a Colorado-based medical cannabis dispensary. Due to the broad ownership of Cannabis Science, a public company with shareholders around the world, and the fact that no specific element(s) of the new Colorado legislation permits or inures the same resident-based ownership rights to a public company, the Company's legal counsel advised management to cancel the May 8th RockBrook acquisition, which Mr. Pasquale also agreed with. On July 30, 2010, we signed a Mutual Termination Agreement ("MTA") with RockBrook Inc. and its sole shareholder, Mr. Adam Pasquale. We are pleased that a mutually beneficial business relationship was reached with Mr. Pasquale and RockBrook, Inc. under the new legislation regulating Medical Marijuana in the State of Colorado."

About RockBrook, Inc., www.RockBrookInc.com

Our dispensary prides itself in providing the highest quality medical marijuana medicines. When the question of potency is out of the way, the patient can better identify the right strain(s) to find an optimal balance. RockBrook also welcomes edibles from Gaea's Harvest and other infused products made with Cannabis Science, Inc. oversight! We look forward to meeting all of you and providing you the type of experience you deserve! Our premium quality medicines include RockBrook BlueBerry (50/50), Afghani Kush (AK), White Widow, The Pink, Sour Diesel, Pineapple, Sweet Island Skunk, Maui Wowie, Flow, BlueCheese, BigWreck as well as a variety of proprietary strains. We are located near the intersection of S. Colorado Blvd and Yale. Our office is in the Robinson Law Building (across from SunFlower Market) on S. Colorado Blvd. We are open from 11:00am to 6:00pm (Tuesday to Saturday) Please call in advance for an appointment to ensure that we can provide you with the time you deserve! RockBrook, Inc. 2865 S. Colorado Blvd, Suite 323, Denver, CO 80222. Phone - 303.756.0595 info@rockbrookinc.com

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based Cannabis Science Brand of Pharmaceutical Products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Cannabis Science, Inc.

By Staff

CONTACT: CONTACT: Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
Mark J. Friedman
Investor Relations
1-877-431-CBIS (2247)
info@cannabisscience.com
www.cannabisscience.com

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.

-0-

INDUSTRY KEYWORD: Business Services
SUBJECT CODE: PHARMACEUTICALS
LICENSING AGREEMENTS
Licensing Agreements
Health

8/18/10 Cannabis Science to Pursue Legal Remedies Against Montana Pain Management for Breach of Non-Disclosure/Non-Circumvention Agreement

COLORADO SPRINGS, Colo., Aug 18, 2010 (GlobeNewswire via COMTEX) -- Cannabis Science Inc. (OTCBB:CBIS) ("Cannabis Science, CBIS, or Company"), a pioneering US biotech company developing pharmaceutical cannabis products, reports that Cannabis Science sent an email to Mr. Rick Rosio on July 23, 2010 notifying him that he appeared to be in serious breach of the non-disclosure/non-circumvention agreement ("NDA/NCVA") that he and Montana Pain Management, Inc. ("MPM") had signed with Cannabis Science.

Dr. Robert Melamede, Ph. D., Cannabis Science Inc., President and CEO said, "We are extremely disappointed that the actions taken by Mr. Rosio to deliberately breach a non-disclosure/non-circumvention agreement by contacting and conducting business with a scientific advisor of the Company, Dr. Arturo Morales. For Mr. Rosio to use that breach as the basis for Montana Pain Management to cancel the signed Share Purchase Agreement is even worse. MPM, we have learned, has engaged Dr. Morales as COO and is to invest directly into MPM. This blatant breach not only damages the reputations of Mr. Rosio, MPM, and Dr. Arturo Morales by circumventing binding legal agreements, but it also demonstrates a lack of moral and ethical character in addition to not acting in good faith. The expertise and credibility that Dr. Morales is now bringing to MPM, as asserted by Mr. Rosio, is the same expertise and credibility that would have remained with Cannabis Science but for his breach. While Dr. Morales was not under an exclusive scientific advisory role with the Company, Mr. Rosio and MPM were legally bound to not approach Dr. Morales or enter into any circumventing agreements with him without the express written authorization of Cannabis Science."

Cannabis Science was informed that Mr. Rosio, without Cannabis Science participation or approval, was consummating a complete investment and buyout deal with Dr. Arturo Morales. Cannabis Science, while under the signed non-disclosure/non-circumvention agreement, introduced Mr. Rosio to Dr. Arturo Morales. At the time Dr. Arturo Morales was on the scientific advisory board of Cannabis Science.

On July 22, 2010, the day before Cannabis Science notified Mr. Rosio of his serious and evident breach of the non-disclosure/non-circumvention, Rick Rosio, the principal shareholder of MPM, notified Cannabis Science that he/it was not proceeding with the Share Purchase Agreement to complete the sale of MPM.

The following is excerpted from the email notice received by Dr. Robert Melamede, President and CEO of Cannabis Science, from Mr. Rick Rosio, the principal shareholder of MPM on July 22, 2010:

"Gentlemen: I will not be signing either the Stock certificates or the Stock Power document presented by you to close our transaction… MPM has reached an Agreement with Dr. Morales. The resources he is willing and able to provide today, will take MPM to the exportable clinic model we all envision. His immediate purchase of MPM shares with cash, will pay my employees, build and maintain Darby, and clear out short-term debt. At the same time my company acquires a COO with his expertise and most importantly credibility. I also sincerely hope that CBIS will still be interested in pursuing a new agreement with MPM. I do not know exactly what that looks like, but I would hope that you would now be even more interested in MPM... I am very interested in renegotiating MPM's relationship with CBIS as I still believe that there is much to be gained by our synergies… I reiterate that I sincerely hope to reach a new agreement with CBIS and we should begin those discussions immediately. However, any new agreement will be noticeably different in terms of immediate funding and managerial decision making of MPM's operations."

Per the NDA/NCVA, Mr. Rosio signed on June 11, 2010, Cannabis Science is of the opinion he and MPM breached the following section of the Agreement in negotiating and doing business with Dr. Morales:

"4. Non-Circumvent: Each party agrees not to circumvent each other, or compete with each other. Neither party will attempt to circumvent the other party by contacting any person, company or entity introduced to them by the other party, or any of the other party's customers, distributors, clients, consultants, agents or the like, anywhere in the world without the express authority of, and in the interest of both parties."

On July 23, 2010, Dr. Morales notified the Company via email that his name was to be withdrawn from the Cannabis Science advisory board and that all future communications should be directed through the Bjornson Law Office, which also represented Mr. Rosio and MPM in the Share Purchase Agreement with the Company.

Richard Cowan, Cannabis Science CFO, added, "It is very apparent from Mr. Rosio's actions and communications that he did not act in good faith or adhere to legally binding agreements he had signed. When Mr. Rosio saw the opportunity to secure the expertise, credibility and financial resources of Dr. Morales, who was a scientific advisor of Cannabis Science when he was introduced to him, Mr. Rosio blatantly breached his NDA/NCVA commitments to CBIS. It's extremely disconcerting to learn that Mr. Rosio feels we would be best served by immediately renegotiating a new deal with MPM when he showed blatant disregard for previously existing legal agreements. There are identifiable losses to Cannabis Science because of his actions, one of which is Dr. Morales withdrawing his services as scientific advisor to the Company, and we will now work with our legal team to pursue all legal remedies and to seek restitution for Cannabis Science and its shareholders."

Management of the Company is currently consulting with legal counsel and intends to proceed with legal action against MPM and its principal shareholder, Mr. Rosio, for breach of the NDA/NCVA that was entered into on June 11, 2010.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements: This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Cannabis Science, Inc.

By Staff

CONTACT: CONTACT: Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
Investor Relations
Mark J. Friedman
1-877-431-CBIS (2247)
info@cannabisscience.com
www.cannabisscience.com

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.

-0-

INDUSTRY KEYWORD: Business Services
SUBJECT CODE: HEALTH
LAW
LEGAL
Law & Legal Issues

Looking good so far!

All that is saying is no more new facilities in Butte, "It’s just getting out of hand,' Palmer told The Montana Standard on Monday. 'We need to take a step and say no more shops until the Legislature decides what to do with it.” That is actually good for existing businesses imo. Also notice how it is up to the legislature which is what I posted about...

Prop. 19 Continues To Lead In Latest Poll

August 17th, 2010 By: Paul Armentano, NORML Deputy Director

A majority of Californians continue to voice their support for Prop. 19 — which would eliminate penalties for the private possession and use of marijuana by adults, and allow local governments to regulate retail cannabis production and sales.

According to the most recent Survey USA poll (conducted August 9-11), 50 percent of likely voters in California say they are certain to vote ‘yes’ on Proposition 19 versus 40 percent who say that they will vote ‘no.’ These totals are the same as reported by Survey USA one month ago, and indicate that voters’ support is holding steady despite increased attacks and propaganda from our opponents. (NORML Outreach Coordinator Russ Belville has just posted an excellent rebuttal to many of our opponents’ more outrageous claims here.)

According to the latest polling data, voters age 35 to 49 are most likely to back Prop. 19, and African Americans and self-reported Democrats are more likely to support the measure as compared to other groups. (To read why self-proclaimed ‘conservative’ voters ought to vote yes on Prop. 19, please see my recent op/ed in the Orange County Register here.) On Friday, leaders from the Latino Voters League held a press conference in Los Angeles announcing their support for Prop. 19, joining the state NAACP which had previously announced their ‘unconditional support’ for the measure in June.

Predictably, many members of law enforcement continue to speak out against the measure. Yet, as you can see in my recent rebuttal to three Bay area police chiefs, their rhetoric rings hollow. In fact, even those in the media who oppose Prop. 19 are beginning to question the rhetoric and tactics of LEOs.

Fortunately, editors at several prominent California papers are giving ample editorial space to getting out the facts regarding Prop. 19. Recently, I’ve had op/eds published in the San Jose Mercury News (“Critics of Prop. 19 on marijuana rely on fear, not facts“), The Los Angeles Times (“Feinstein’s misguided opposition to marijuana legalization“), and The Ventura County Star (“Media’s coverage of report spurs reefer madness“) setting the record straight.

Bottom line: The status quo in California for non-medical patients is an abysmal failure. California lawmakers criminalized the possession and use of marijuana in 1913 yet right now in California, the federal government reports that one out of 10 people annually use marijuana and together consume about 1.2 million pounds of it. Self-evidently, cannabis is here to stay. Let’s address this reality and end the practice of arresting 70,000+ Californians each year for minor marijuana possession and/or cultivation charges, and lets stop ceding control of the commercial marijuana market to unregulated, untaxed criminal enterprises and put it in the hands of licensed businesses. Proposition 19 is a first, significant step in this direction.

http://blog.norml.org/2010/08/17/prop-19-continues-to-lead-in-latest-poll/

Very beautiful indeed

Rockbrook, Inc.: CBIS' other dispensary

RockBrook, Inc. Meds (from facebook):













Epic Nug!

Review of Montana Pain Management by Michael Nevas

* March 15th, 2010 9:12 pm

Montana Pain Management


Occupying their own small building on 3rd Street between Russell and Reserve, Montana Pain Management MPM serves their patients cannabis products from their store every day of the week, from 9 am- 6pm on weekdays and from 10am -3 or 4pm on weekends. At around 11:30am on Monday, March 15 I squeezed my car into their parking lot and walked inside for a gram of their best chronic pain relief.

The most important factors that I look for in a cannabis dispensary are Price, Product, Staff, and Storefront.

Price: 4 ½ Stars: Although the cannabis was $10 per gram, the cookie I bought cost $8, which is not exorbitant, however that is at least $2 more than what a cannabis cookie should cost anyways. MPM’s ability to take credit cards and provide $35 eights should earn them 5 stars, however their expensive little cookies drag them down to 4 ½ stars.

Product: 4 Stars: The AK-47 that I rolled into a joint went down very smoothly and provided a decent duration of effect (as well as a killer smell and taste), and although it tasted a bit too “herbish”, the cookie did a commendable job of relaxing my muscles. If MPM managed to increase their selection of A grade cannabis and baked goods, that would push them over the edge to 5 stars, but for now I must leave them dangling at 4 ½ stars .

Storefront: 4 Stars: Despite the highly visibility of their location, patients are given a large degree of privacy when conferring with caretakers in private offices or taking a comfortable seat in their large waiting room. The cannabis showing room is actually a converted kitchen with a computer that’s broken down both times I’ve visited in the past month, and when tiny parking lot is factored in, MPM is left with a slightly cramped 4 stars.

Staff: 4 Stars: The moment I walked in the door I was greeted with a smile by Libby, their receptionist, before a smiling young man named Logan showed me into the smaller room in back to choose my medicine. While very helpful and polite during our interactions, he did not describe the cannabis he was showing me, and he did not display the encyclopedic knowledge of their own marijuana that I've come to expect from dispensary staff; they could get 5 stars if their staff knew a bit more about the strains they are selling and engaged more thoroughly with their customers, however 4 stars still gives them a highly respectable showing.

Out of 20 available stars, MPM earned 16 ½ ; I may visit this establishment again and I would certainly recommend this dispensary to a friend.

http://www.examiner.com/medical-marijuana-in-missoula/review-of-montana-pain-management

Note: This was a review from 5 months ago

Medical marijuana dispensaries, doctor restrictions win Montana legislators' backing

HELENA - An interim legislative subcommittee tentatively agreed Thursday on some proposals to restrict Montana's fast-growing medical marijuana industry.

The Medical Marijuana Subcommittee spent the day informally voting on various proposals that will be incorporated in draft legislation to be considered by the Legislature's Children, Families, Health and Human Services Interim Committee on Aug. 23-24. The 2011 Legislature ultimately will decide on the issue.

Afterward, the chairwoman, Rep. Diane Sands, D-Missoula, said she believed two of the subcommittee's actions were especially significant - the call for a new dispensary system and restrictions to prevent physicians being financially involved with medical marijuana caregivers or dispensaries.

The committee voted to recommend that Montana become a "dispensary system" through which people with medical marijuana cards could buy marijuana through dispensaries, or stores, that are designated as their caregivers. Legislators voted to use the recently enacted Colorado law as their model.

Colorado, Maine, New Mexico and Rhode Island recently adopted dispensary systems that require all principal officers, board members, managers and employees to undergo background checks and be licensed by the state, according to a report by legislative researcher Sue O'Connell.

***

Under the proposal, the state would be allowed to inspect the facilities or any growing operations and examine sales records. The panel tentatively approved having dispensaries regulated by the state Revenue Department as the state agency does with establishments that sell alcoholic beverages.

As of June, nearly 20,000 Montanans had medical marijuana cards, with the number soaring since last fall after the U.S. Justice Department directed law enforcement agents not to arrest medical marijuana users and suppliers as long as they follow state laws.

Sands said one provider predicted that number could escalate to 50,000 Montanans by the time the Legislature convenes in January. She raised the specter that 100,000 people, more than 10 percent of the Montana population, might qualify for medical marijuana cards if they claim "severe chronic pain," one of the criteria needed to obtain the card.

Rep. Penny Morgan, R-Billings, noted that a staff report showed that 2 percent of Montana's population has medical marijuana cards, compared with 0.13 percent in Alaska, 0.62 percent in Colorado, 0.95 percent in Oregon and 0.03 percent in California.

"Why it is that people in Montana are so disabled that they need this so much?" she asked. "In my opinion, there are a lot of people getting cards who shouldn't have them. This is not normal with the rest of the country."

The subcommittee would still allow for caregivers, to be called providers, who grow or buy marijuana. They would be able to sell it to an as yet undermined number of patients.

Sen. Rick Laible, R-Victor, proposed limiting one caregiver to five patients, but later dropped the idea. The panel voiced support for some sort of a tiered system for caregivers, such as limiting a caregiver to three and fewer patients, from three to five patients and so on, with stiffer regulation the more patients a caregiver saw, but it didn't settle on a number yet.

Laible supported the dispensary system idea, saying: "We won't need as many caregivers except for people who are disabled."

Some caregivers in the audience testified they wouldn't be able to survive financially if they could serve only five patients and would have to get additional jobs.

"If you limit caregivers to five patients, you will have more caregivers, not less," said Valerie Sigler. "This (growing marijuana) is not an easy thing to do. It takes quite an investment. It takes time. It's a full-time job."

Rick Rosio, owner of Montana Pain Management of Missoula, opposed limiting the number of patients for caregivers. He said his business now provides marijuana to 100 patients a day, day in and day out, all across the state.

"To impose a five-patient limit will kill almost every operation in the state," said Chris Lindsay.

***

Another key change recommended by the panel would prohibit a doctor from being paid or soliciting pay from caregivers and dispensaries. It also would be illegal for a physician from holding an economic interest in a business if that doctor certifies the "debilitating medical condition" that allows a patient to participate in a medical marijuana program.

Sands said statistics show that many physicians have authorized medical marijuana cards for a small number of patients. However, she said there are a handful of doctors who have approved medical marijuana cards for many, many people.

Imposing these financial restrictions on physicians should stop this practice, she said.

Afterward, Bill Boast, a Kalispell caregiver, said he would probably oppose the bill as written for a number of reasons.

"They don't limit a pharmacy as they have my clients," he said. "Wal-Mart can sell Oxycontin to as many people (with prescriptions) as they want."

Missoulian State Bureau reporter Charles S. Johnson can be reached at (406) 447-4066 or at chuck.johnson@lee.net.

http://www.mtstandard.com/news/state-and-regional/article_a0d399e6-a6d3-11df-9659-001cc4c002e0.html

Montana Pain Management: CBIS' dispensary

Come on in!




Now lets take a look at the grow operation!







Quantity and quality!